Osoyoos Cannabis Inc. (CSE:OSO) (“Osoyoos” or the “Company”) and Anahit International Corp. (“Anahit” or “Target”) are pleased to announce today that they have entered into a non-binding letter of intent (“LOI”), which subject to, among other things, due diligence of each party, the negotiation and execution of a definitive agreement, certain conditions and applicable Canadian Securities Exchange (“CSE”) approval, will result in the reverse takeover of Osoyoos by Anahit (“Proposed Transaction”). After completion of the Proposed Transaction, the shareholders and certain convertible security holders of Osoyoos will hold approximately 20% of the issued common shares of the resulting issuer, with current shareholders and convertible security holders of Anahit holding approximately the remaining 80%, on a partially-diluted basis, as further noted below.

If completed, the Proposed Transaction will constitute a Fundamental Change, as such term is defined in the policies of the CSE. Osoyoos’ shares have been halted and will remain so until the CSE has reviewed and approved the Proposed Transaction.


Commentary from Gerry Goldberg, Interim CEO of Osoyoos Cannabis Inc.:

“We are very pleased to announce the entering of the LOI with Anahit International Corp. as a first step to potential completion of the Proposed Transaction. Assuming completion of the Proposed Transaction, going forward, Osoyoos intends to operate as a division of Anahit and continue to execute on Anahit’s corporate initiatives. As such, Osoyoos will represent a portion of Anahit’s Canadian footprint and be amongst a broader portfolio of global assets. We believe the combination of these aligned businesses will substantially increase Osoyoos’ shareholder value.”

Overview of Anahit International Corp.

Anahit is a Toronto-based company with a focus on international cannabis operations and is committed to leveraging its Canadian expertise around the world. This includes operations in emerging, regulated jurisdictions where climates are conducive to low-cost, high-quality outdoor cannabis cultivation, processing, and product development.

Anahit’s international operations are supported by Canadian and U.S. experts, who are introducing Health Canada approved methodologies to Anahit-owned (or leased) farms and operations, including: cultivation, extraction, storage, and product development. This team of experts consists of members from Canada, Colorado and California, with a depth of experience in extraction, product creation, and management of retail locations. Anahit’s commitment is to leverage this expertise into developing economies in a manner that is responsible, accessible and economical. Anahit is committed to supply the global market with high-quality products that meet and surpass Canada’s high standards. In this endeavor, Anahit has specifically targeted jurisdictions in which its operations will be able to achieve this benchmark. Across these countries, advancements in cannabis regulations have advanced substantially and this will enable Anahit to take advantage of operating in these international markets.

Anahit currently has over 15 new cannabinoid products in development, including medical and over the counter health and wellness products. The Company has the ability to rapidly produce high quality products in a low-cost and high throughput environment. Through its partnership with the University of Guelph, Anahit is commercializing certain technology to make novel anti-inflammatory medications from cannabis.

Anahit’s Portfolio of International Assets

Jamaica

Jamaica is one of the most exciting international markets and presents a significant opportunity to obtain unique strains, cultivate premium flower and develop high value products. Anahit has received conditional approval for Cultivator’s Licenses across three sites, which will allow Anahit to cultivate cannabis outdoors on at total of 26.5 acres. Additionally, Anahit has conditional approval for two Processing Licenses and an Herb House License for local retail sales. Outdoor cultivation will operate year-round and yield four crops per year, which will be processed in Anahit’s GMP extraction facilities.

Columbia

Colombia has established a robust cannabis regulatory framework and offers an ideal climate for year-round cultivation. Anahit is in the process of acquiring cultivation, extraction, seed, local sales and export licensing. In addition to this, Anahit has local distribution contracts with hospitals and pharmacies. Anahit will begin cultivation on 20 hectares of land, with an option to expand by an additional 20 hectares. The acquisition of the license includes greenhouse cultivation facilities and the initial build out will include a GMP extraction facility.

Greece

Anahit is in the process of acquiring a facility for the purpose of cultivating and processing cannabis in Greece. Once completed, Anahit is expected to be among the first holders of such licenses. The site contains 1 hectare of glass and canopy greenhouses with an option to expand onto an additional 7 hectares of adjacent land. Phase 1 will include an EU GMP certified processing facility which will provide medical oils and over the counter CBD products derived from hemp. These products will be sold across 11,000 local pharmacies and for export into other EU markets. Phase 2 relates to the acquisition of a THC license, which is anticipated to be received approximately 90-days after the cultivation license related to hemp in Phase 1 is received.

The Proposed Transaction

Pursuant to the LOI, dated May 15, 2019, upon the completion of the Proposed Transaction:

  1. The outstanding common shares in the capital of the Target (the “Target Shares”) will be exchanged for common shares in the capital of the Company (the “Company Shares”), whereby each holder of a Target Share will receive one 3.53010365193 Company Shares for each Target Share held (the “Exchange Ratio”) (such issuance not including Company Shares to be issued or issuable under the Target future obligations). Following the above exchange it is agreed that the former Company shareholders (on a partially diluted basis taking into account the 12,308,330 warrants exercisable at prices ranging from $0.20 to $0.45) will hold twenty percent (20%) and former Target shareholders (on a partially diluted basis) will hold eighty percent (80%) of the issued and outstanding shares of the resulting issuer.
  1. All outstanding options, warrants and future obligations to issue Anahit common shares will be exchanged with options, warrants and future obligations to issue common shares in the resulting issuer in accordance with the Exchange Ratio. The Exchange Ratio will be adjusted as is necessary to effect the ratio of 20 percent to 80 percent prior to closing of the Transaction in accordance with the terms of the LOI.
  1. Osoyoos will change its name to “Anahit International Corp.”, or such other name as may be acceptable to Anahit, the CSE, and regulatory authorities.
  1. The board of directors of the resulting issuer will be reconstituted to be comprised of five (5) directors, four of which will be nominees of Anahit and one of which will be a nominee of Osoyoos. Management of the resulting issuer will be fully comprised of Anahit representatives.

Closing Conditions

Closing of the Proposed Transaction is subject to negotiation, completion and execution of a definitive agreement and all ancillary definitive transaction documents as well as customary conditions, including the satisfaction of each party with the results of its due diligence investigation, receipt of all required shareholder, board, third party and regulatory consents and approvals and the satisfaction of other closing conditions.

About Osoyoos Cannabis Inc.

Osoyoos Cannabis Inc. is an early-stage cannabinoid extraction company based in Oliver, BC. Osoyoos Cannabis has applied for a standard processing license under the Cannabis Act for its 10,410 ft2 facility and that application is currently in the review stage. The Company will offer contract tolling extraction, sale of bulk oil and development of both proprietary Osoyoos Cannabis branded and white labelled products once licensed to do so.

For further information, please contact:

Osoyoos Cannabis Inc.
Gerry Goldberg, Interim CEO
Phone: (416) 460-3000

The CSE has in no way passed upon the merits of the Proposed Transaction and has neither approved or disapproved the contents of this press release.

Notice Regarding Forward‐Looking Information

This news release contains certain “forward‐looking information” within the meaning of applicable Canadian securities law. Forward‐looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Readers are cautioned that forward‐looking information contained in this new release is not based on historical facts but instead is based on reasonable assumptions and estimates of management. Forward‐looking information contained in this news release includes, but is not limited to: the expected utility of and impact on operations of Anahit; the timing and success of license applications by Anahit. Further, this news release contains information provided by third‐party sources, including information regarding the properties, characteristics and relative timing of the development of Anahit’s international operations have not been independently‐verified by Osoyoos. Forward‐looking information contained herein is based on the opinions and reasonable assumptions and estimates of management as at the date hereof and is subject to a variety of known and unknown risks and uncertainties and other factors, many of which are beyond the control of Osoyoos, that could cause actual events or results of Osoyoos to differ materially from those expressed or implied in the forward‐looking information. Such factors include: the requirement by Osoyoos to obtain additional financing, the limited operating history of Osoyoos, timeliness of government approvals for granting of permits and licences needed by any future investee companies, including licenses to cultivate cannabis, the actual operating and financial performance of any future investee company, competition and other risks affecting Osoyoos. Because of such risks, uncertainties and other actors, investors should not place undue reliance on the forward‐looking information contained herein. Osoyoos is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward‐looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. The foregoing statements expressly qualify the forward‐looking information contained herein. This release does not constitute an offer for sale of, nor a solicitation for offers to buy, any securities in the United States.

Click here to connect with Osoyoos Cannabis Inc. (CSE:OSO) for an Investor Presentation. 

Source: www.newsfilecorp.com

Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less